Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
GAITHERSBURG, Md., Oct. 13, 2017 -- Novavax, Inc., (Nasdaq:NVAX) announced today that Barclay A. “Buck” Phillips has submitted his resignation as Senior Vice President, Chief Financial Officer (CFO) and Treasurer, to pursue an expanded opportunity in the industry. Mr. Phillips will step down effective November 10, 2017, and will provide financial, accounting and transition services as a consultant to Novavax until December 31, 2017. Mr. Erck will act as the interim CFO pending completion of a search for a new Chief Financial Officer.
“Buck has been instrumental in a number of significant Novavax accomplishments, and we thank him for all his contributions over the last four years. We wish him all the best in his new endeavors,” said Stanley C. Erck, President and CEO of Novavax.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
[email protected]
240-268-2000
